Boone Capital Management LLC holds a focused book of 16 reported positions worth $427.5M as of Q2 2026 (disclosed Aug 14, 2026, a ~45-day 13F lag). This quarter they opened Vestis Corp and trimmed Mirum Pharmaceuticals Inc. Their largest long position is Teleflex Inc at 11% of the reported non-option book. Cloning the disclosed picks since 2023 would be +12% (+3.2%/yr). That is a simulation of the disclosed long book, not audited returns.
The reported book (valued from quarter-end) returned +26.5%, a 14.7-point gap that is the cost of the ~45-day 13F disclosure lag a real follower can't avoid.
Growth of $10,000 cloning Boone Capital Management LLC's disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~45 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices (an exit at the prior quarter-end), no cost basis
Other tracked managers holding the same core names as Boone Capital Management LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| Boxer Capital Management, LLC | 3 / 16 | $446.8M |
| Frazier Life Sciences Management, L.P. | 3 / 16 | $1.0B |
| BVF Inc | 4 / 16 | $780.3M |
| TCG Crossover Management, LLC | 5 / 16 | $583.8M |
| Tweedy, Browne Co LLC | 3 / 16 | $184.6M |
| MPM BioImpact LLC | 3 / 16 | $227.6M |
| Bayban | 2 / 16 | $16.1M |
| Eagle Health Investments LP | 3 / 16 | $70.2M |
Ranked by the share of each fund's own book sitting in the names it shares with Boone Capital Management LLC: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each position's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Teleflex Incorporated COM | $49.1M | 387.4K | 11.5% | ▲+39% Added · +109K sh | |
| 2 | Mirum Pharmaceuticals Inc COM | $48.7M | 415.6K | 11.4% | ▼−1.3% Reduced · −6K sh | |
| 3 | The Cigna Group COM | $43.9M | 159.3K | 10.3% | ▲+16% Added · +22K sh | |
| 4 | Ionis Pharmaceuticals Inc COM | $41.2M | 520.0K | 9.6% | ▲+3.9% Added · +19K sh | |
| 5 | Unitedhealth Group Inc COM | $36.9M | 88.7K | 8.6% | ▲+12% Added · +9K sh | |
| 6 | Biomarin Pharmaceutical Inc COM | $33.4M | 583.2K | 7.8% | ▲+6.5% Added · +35K sh | |
| 7 | Guardian Pharmacy Svcs Inc CL A | $29.8M | 711.9K | 7.0% | ▲+13% Added · +81K sh | |
| 8 | Vestis Corporation COM SHS | $27.6M | 1.90M | 6.5% | ▲New New position | |
| 9 | Bridgebio Pharma Inc COM | $25.3M | 339.7K | 5.9% | ▲+48% Added · +111K sh | |
| 10 | Pennant Group Inc COM | $19.1M | 515.8K | 4.5% | ▲New New position | |
| 11 | Monte Rosa Therapeutics Inc COM | $14.9M | 615.3K | 3.5% | ▲New New position | |
| 12 | Kodiak Sciences Inc COM | $14.7M | 378.0K | 3.4% | ▲+34% Added · +97K sh | |
| 13 | Tango Therapeutics Inc COM | $14.2M | 455.6K | 3.3% | ▲New New position | |
| 14 | Kymera Therapeutics Inc COM | $13.0M | 113.2K | 3.0% | ▲New New position | |
| 15 | Cullinan Therapeutics Inc COM | $12.8M | 704.4K | 3.0% | ▲New New position | |
| 16 | Adlai Nortye Ltd SPONSORED ADS | $3.0M | 258.4K | 0.7% | ▲New New position |
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1882053/holdings"
Use Arkolith to show BOONE CAPITAL MANAGEMENT LLC's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Reported 13F total per quarter. Raw filing totals can include option notional.
| Quarter | As of | Filed | Lag | Positions | Value | Form |
|---|---|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | Aug 14, 2026 | 45d | 16 | $427.5M | 13F-HR |
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 45d | 13 | $326.4M | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 48d | 15 | $318.6M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 45d | 16 | $305.0M | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 45d | 11 | $233.2M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 45d | 12 | $293.8M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 45d | 13 | $296.5M | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 45d | 17 | $385.8M | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 45d | 19 | $383.4M | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 45d | 21 | $494.4M | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 45d | 21 | $428.4M | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 45d | 13 | $317.0M | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 | 45d | 13 | $278.6M | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 45d | 12 | $213.6M | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 45d | 17 | $194.9M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. Book totals and portfolio weights cover reported non-option positions, which can include notes and warrants. Disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.